Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participant will get is decided by chance. The study will last for about 8 months.
Sponsor: Novo Nordisk A/S
Where it's recruiting
Walnut Creek
Fleming Island · Jacksonville · Pembroke Pines · Weston
Monroe · Wilmington
North Charleston
Bristol
Amarillo · Austin
Source: ClinicalTrials.gov · NCT07607587 · last updated 2026-06-25